The Smartest Ways to Invest in CBD Growth Right Now

Palm Beach, FL – November 13, 2019 — CBD is quickly becoming a multi-billion-dollar business.  In fact, sales of products containing CBD are expected to grow 700% in 2019 year over year, says the Brightfield Group.  “The CBD market has been growing rapidly, but we will see unprecedented growth in 2019,” Brightfield Managing Director, Bethany Gomez, explains. “The bulk of this growth is coming from large retailers like CVS, Walgreens, and Kroger entering the market and providing that availability to consumers.”  Better, more Americans are supportive of cannabis legalization.  In fact, according to a Gallup survey, 66%  of Americans are in favor of legalization. That’s up from just 60% in 2016.  In addition, cannabis has become a major platform for presidential candidates, as we near the 2020 presidential election.  That’s leading to a wide range of opportunity for companies including CBD Global Sciences, Inc. (CSE: CBDN), Curaleaf Holdings Inc. (CSE:CURA) (OTCQX:CURLF), CV Sciences Inc. (OTCQB:CVSI), HEXO Corporation (NYSE:HEXO)(TSX:HEXO), and The Supreme Cannabis Company Inc. (TSX:FIRE) (OTCQX:SPRWF).


CBD Global Sciences, Inc. (CSE: CBDN) BREAKING NEWS:  CBD Global Sciences, Inc. announced that Minute Suites, a wellness-based solution for travelers located in airports throughout the United states, has commenced selling Aethics product line, which include CBD Daily Active lotion, Muscle Rescue lotion, among others in locations nationwide. This partnership builds upon CBD Global Sciences’ impressive and expanding distribution network and we anticipate that it will enable us to continue to generate significant growth during the balance of the fourth quarter of 2019 and into the start of 2020. “We are dedicated to offering the highest quality line of CBD products to Minute Suites and their customers, said Brad Wyatt, CEO CBD Global Sciences.  “Working with a trusted retail partner allows us to expand our footprint in the US and Canada.  We are thrilled about Minute Suites decision to expand their CBD offerings with our products.” Top offerings from CBD Global Sciences include Muscle Rescue lotion, Daily Active lotion, CBD Marathon Foot rub, H2O Balance CBD water, and a wide range Performance Drops, CBD Global Sciences’ whole plant CBD oil line. “We are excited for the new partnership between Aethics and Minute Suites, bringing the first retail CBD products to airports nationwide,” says Chris Glass, Chief Operating Officer of Minute Suites.“ As we are focused on delivering the highest quality product possible, the Aethics brand is the foundation of our CBD lineup.”


Other cannabis-related developments from around the markets include:


Curaleaf Holdings Inc. (CSE:CURA) (OTCQX:CURLF) announced the launch of its first Massachusetts adult-use dispensary in Oxford, Massachusetts. The retail store is now open at 425 Main Street in Oxford. Retail store hours are 9AM-8PM, Monday thru Saturday and 10AM – 5PM on Sunday.  The Oxford location will serve customers by appointment only for the first 30 days of operation but on-site appointments can be made schedule permitting.


CV Sciences Inc. (OTCQB:CVSI) announce its support of the U.S. Department of Agriculture’s (USDA) progress on implementation of the hemp provisions of the 2018 Farm Bill. On October 29, 2019, U.S. Secretary of Agriculture Sonny Perdue announced the interim final rule for the U.S. Domestic Hemp Production Program. USDA regulation of hemp farming provides a consistent regulatory framework that supports responsible and sustainable hemp production in the United States. A strong USDA regulatory framework is needed to differentiate hemp, an agricultural commodity, from marijuana, a controlled substance, and to protect farmers and consumers.  USDA announced that later this week, an interim final rule formalizing the program will be published in the Federal Register. This will allow hemp to be grown under federally-approved plans and make hemp producers eligible for agricultural programs, like crop insurance. The rule includes provisions for USDA to approve hemp production plans developed by states and Indian tribes including: requirements for maintaining information on the land where hemp is produced; testing the levels of THC to ensure compliance with the law; disposing of noncompliant plants; and licensing requirements. “We are eager to see full implementation of USDA’s Hemp Production Program,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “The hemp industry is poised for rapid growth that will create new jobs and economic development opportunities for farmers, rural communities and the CBD industry. Regulatory clarity is critical for the hemp industry and we believe the interim final rule is another step toward the proper regulatory framework that will help unlock the true domestic growth potential of the industry. We’d like to thank the U.S. Hemp Roundtable and its hemp industry members for their tireless efforts in achieving this milestone. Now that hemp farming regulations have been established its time to focus on FDA’s work to clarify the regulatory pathway for hemp-derived CBD products in dietary supplements. USDA and FDA regulation of hemp and CBD will provide a level playing field for quality and science-based CBD companies to operate, and allow consumers access to safe and beneficial products.”


HEXO Corporation (NYSE:HEXO)(TSX:HEXO) just announced it has received licenses from Health Canada for its cannabis Centre of Excellence in Belleville, Ontario, for research, and for the sale of cannabis topicals, extracts, edibles and beverages from its flagship Gatineau campus. “The research license will allow us to take our innovation work to the next level, with testing on derivative products, including taste testing. Consumers have high expectations for their packaged goods experiences, and cannabis will be no different,” said Sebastien St-Louis, CEO and co-founder of HEXO Corp. “We are committed to not only ensuring a quality consistent experience but to also guaranteeing that experiences powered by HEXO meet these expectations.” While a Processing License provides for testing on live plants, fresh and dried plant material, seeds, and oil, a Research and Development License significantly expands the scope of work that can be conducted on cannabis and its derivatives. The Company plans to conduct research and development at its Vaughan and Montreal Innovation, Development and Engineering hubs, as well as at its Centre of Excellence in Belleville and in other facilities.


The Supreme Cannabis Company Inc. (TSX:FIRE) (OTCQX:SPRWF) announced that it will be providing its first quarter financial results for the three months ended  September 30, 2019 on November 14, 2019.  The Supreme Cannabis Company is a global diversified portfolio of distinct cannabis companies, products and brands. Since 2014, the Company has emerged as one of the world’s fastest-growing, premium plant driven-lifestyle companies by effectively deploying capital, with an emphasis on disciplined growth and high-quality products.


DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates and, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated thirty five hundred dollars for news coverage of current press releases issued by CBD Global Sciences Inc., by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.


Contact Information:

Media Contact email: – +1(561)325-8757